News Categories
Resources For Living
Mesothelioma Forum
Legal Help Blog
Find a Doctor Near You
Mesothelioma Blog
Latest News
- Mesothelin Finding Could Lead to Early Detection of Mesothelioma
- New York Attorney Calls for International Ban on Mesothelioma-Causing Asbestos
- Protein Can be Reliable for Diagnosing Malignant Mesothelioma
- Biomarker Successes Remain Elusive For Mesothelioma and Cancer Researchers
- Avastin May Not be Effective for Breast Cancer, But is Still an Option for Mesothelioma
- Options for Funding Mesothelioma Research
- Golf Outing to Raise Funds for Mesothelioma Research
- 3 Year Mesothelioma Survivor Stays Busy Raising Awareness of the Disease
- MesotheliomaHelp Website Offers Mesothelioma-Related FAQs
- CDMRP System Offers Funding Opportunity to Help Military Mesothelioma Sufferers
Wednesday, October 21, 2009
Simcere Pharmaceutical Group, a Chinese pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals, has joined forces with OSI Pharmaceuticals, Inc. of the United States, to develop, manufacture, and market its KDR/Kit inhibitor OSI-930 in China.
OSI, based in Long Island, NY, specialized in the discovery and development of innovative molecular targeted therapies. OSI-930 targets both cancer cell proliferation and blood vessel growth (angiogenesis) in selected tumors. In preclinical studies, OSI-930 shows broad efficacy in small cell lung cancer, non-small cell lung cancer, colorectal, gastric and other cancers. The drug is also being tested for the treatment of mesothelioma.
Dr. Colin Goddard, Chief Executive Officer of OSI Pharmaceuticals said, “As a leading Chinese pharmaceutical company with a successful track record of developing and commercializing oncology products in China, we are confident that Simcere has the right capabilities and resources to successfully manufacture, develop and market OSI-930 in China.”
According to the World Health Organization, China will have the world’s highest number of lung cancer patients, close to 1 million a year by 2025, if smoking and pollution are not effectively curbed.
Simcere stocks (NYSE: SCR) rose 10% yesterday after the news was announced.
Reference NCT00603356 on ClinicalTrials.gov for further information on OSI-930.
Labels: mesothelioma, Treatment News
posted by Nancy Meredith at 9:03 AM
